- The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age.
- Ocugen Inc (NASDAQ: OCGN) is working with the vaccine’s developer, Bharat Biotech of India, to bring Covaxin to the U.S.
- Related: FDA Lifts Clinical Hold On Ocugen’s COVID-19 Vaccine Study In US.
- Specific details to refuse the EUA were not disclosed.
- Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.
- Price Action: OCGN shares are down 23.10% at $2.53 during the premarket session on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.